Form 4: Incyte Director Jean-Jacques Bienaime Reports Significant Equity Awards

Incyte Corporation Director Jean-Jacques Bienaime reported the acquisition of 2,518 restricted stock units and 9,216 non-qualified stock options on June 10, 2025, as part of his compensation.

Summary

• Jean-Jacques Bienaime, a Director of Incyte Corporation (INCY), reported new equity awards on June 10, 2025.
• He acquired 2,518 shares of Common Stock in the form of Restricted Stock Units (RSUs) at a grant price of $0.
• These RSUs are set to vest in full on the first anniversary of the grant date, or earlier upon the next regular annual meeting of the Company's stockholders or a change of control.
• Following this transaction, his beneficial ownership of common stock, including unvested RSUs, totals 20,841 shares.
• Additionally, he acquired 9,216 non-qualified stock options with an exercise price of $70.07.
• These options also vest in full on the first anniversary of the grant date, or earlier upon the next regular annual meeting of the Company's stockholders or a change of control, and are exercisable until June 9, 2035.
• A Power of Attorney was executed on August 2, 2024, by Jean-Jacques Bienaim, authorizing specific individuals to file Forms 3, 4, and 5 on his behalf.

Sentiment

Score: 7

Explanation: The document reports routine equity compensation for a director, which is generally a positive sign of alignment between management and shareholder interests, but it does not contain information that would significantly alter the company's financial outlook or operations.

Positives

• Director Bienaime received new equity awards (RSUs and stock options), which aligns his financial interests with those of shareholders.
• The awards are structured with vesting conditions (time-based or event-driven), incentivizing long-term commitment and performance.

Risks

• The document includes a standard reminder that intentional misstatements or omissions of facts constitute Federal Criminal Violations, as per 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Future Outlook

The vesting schedules for the acquired Restricted Stock Units and Non-Qualified Stock Options indicate future potential share issuances and exercises, contingent on the director's continued service or specific corporate events like a change of control or the next annual meeting.

Industry Context

This Form 4 filing reflects standard executive compensation practices within the biotechnology and pharmaceutical industry, where equity awards like RSUs and stock options are commonly used to incentivize directors and align their interests with long-term shareholder value. Such awards are a typical component of a director's remuneration package.

Comparison to Industry Standards

• The granting of Restricted Stock Units (RSUs) at a $0 grant price and Non-Qualified Stock Options with a market-based exercise price is a common practice for director compensation in the U.S. biotechnology sector.
• This aligns with compensation structures seen at comparable companies, where equity incentives are used to retain talent and link compensation to company performance.
• Specific comparable companies or projects are not detailed in this filing, as it focuses solely on an individual's transaction.

Corporate Governance

Stakeholder Impact

• **Shareholders:** The equity awards align the director's financial interests with those of shareholders, as the value of the awards is tied to the company's stock performance.

Next Steps

• Vesting of 2,518 Restricted Stock Units on the first anniversary of the grant date (June 10, 2026), or earlier upon the next regular annual meeting of stockholders or a change of control.
• Vesting of 9,216 Non-Qualified Stock Options on the first anniversary of the grant date (June 10, 2026), or earlier upon the next regular annual meeting of stockholders or a change of control.
• Potential exercise of 9,216 Non-Qualified Stock Options by June 9, 2035.

Key Dates

Keywords

Incyte Corporation, INCY, Form 4, Insider Trading, Restricted Stock Units, Stock Options, Director Compensation, Equity Awards, Beneficial Ownership, Corporate Governance